Skip to main content
SpringerLink
Log in

Nanomedicine: Industry-wise research

  • Commentary
  • Published:

From Nature Materials

View current issue Submit your manuscript

Academic participation in nanomedicine research is welcomed by European industries. The recipe for success may or may not include creativity, but it will certainly require awareness of drug development and approval processes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Exotic drugs.

NOBUHIRO NISHIYAMA

References

  1. http://cordis.europa.eu/nanotechnology.

  2. Webster. R. et al. Drug Metab. Disp. 35, 9–16 (2007).

    Article  CAS  Google Scholar 

  3. http://ec.europa.eu/research/fp7.

  4. www.epsrc.ac.uk/Publications/Corporate/StrategicPlan2006.

  5. www.epsrc.ac.uk/ResearchFunding/Programmes.

  6. Owens, J. Nature Rev. Drug Discov. 6, 99–101 (2007).

    Article  CAS  Google Scholar 

  7. Nishiyama, N. et al. Nature Mater. 4, 934–941 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chemistry, UCB, Slough, Berkshire, SL1 4EN, UK

    Mike Eaton

Authors
  1. Mike Eaton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eaton, M. Nanomedicine: Industry-wise research. Nature Mater 6, 251–253 (2007). https://doi.org/10.1038/nmat1879

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nmat1879

  • Springer Nature Limited

This article is cited by

Search

Navigation